<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609099</url>
  </required_header>
  <id_info>
    <org_study_id>NAC-ATB</org_study_id>
    <nct_id>NCT03609099</nct_id>
  </id_info>
  <brief_title>Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response</brief_title>
  <acronym>2017-001406-15</acronym>
  <official_title>Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Garcia Cinca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Miquel Ferrer - Investigator Coordinator</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-inferiority, multicenter, prospective double-blind, randomized clinical trial of two
      parallel groups. The randomization between the 2 study groups will be carried out according
      to a scheme generated by a computer program, in blocks of 6 and stratified by centers. The
      antibiotic treatment will be evaluated during 5 days compared to the usual antibiotic
      treatment for more than 7 days in patients with community-acquired pneumonia with a Pneumonia
      Severity Index IV-V severity score who present an adequate response in the first 4 days of
      hospital antibiotic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double blind treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of treatment failure</measure>
    <time_frame>during the 30 days after the day of hospital admission</time_frame>
    <description>Treatment failure is defined as the appearance of any of the following manifestations: death from any cause, hospital readmission for any cause or restart of antibiotic treatment for any reason.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic-free days</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Antibiotic-free days are defined as the number of days alive and free of antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of serious adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active treatment to patients treated during the 5 previous days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo treatment to patients treated during the 5 previous days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg / day once a day oral treatment during 3 days.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Active treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once a day oral treatment during 3 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes older than 18 years

          -  Hospitalized patients diagnosed with CAP: appearance of a new radiological infiltrate
             plus the presence of at least two of the following signs or symptoms: fever (&gt; 38 °
             C), cough, expectoration, chest pain, dyspnea or tachypnea, and signs of occupation of
             the alveolar space.

          -  That they present a PSI score class IV or V.

          -  Patients who have received adequate antibiotic treatment according to clinical
             guidelines (SEPAR, ATS) ((1,8,19)) from the first hour of admission to the emergency
             room.

          -  Patients who reach clinical stability: temperature ≤37.2 ºC, heart rate ≤100 beats /
             min, respiratory rate ≤24 breaths / min, systolic blood pressure&gt; 90 mmHg; oxygen
             saturation&gt; 90%; or oxygen blood pressure&gt; 60 mmHg (15) before the fourth day.

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Immunosuppression: Co infection with HIV and presence of AIDS, treatment with
             neutropenic effect or have received immunosuppressive treatment for any reason.
             Patients that are in chronic use of corticosteroids as prednisone or its equivalent
             with &gt; 10 mg / day for 14 days.

          -  Patients hospitalized in the previous 14 days.

          -  Patients with pleural effusion

          -  Suspected multiresistant germs of any cause.

          -  Hypersensitivity or alterations in the tendons associated with the fuoroquinolones.

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adrian Ceccato, MSD</last_name>
    <phone>+34.93.227.54.00</phone>
    <email>aceccato@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Almirall, MD</last_name>
      <phone>+34.93.741.77.00</phone>
    </contact>
    <investigator>
      <last_name>Jordi Almirall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Galdakao-Usansolo</name>
      <address>
        <city>Galdakao</city>
        <state>Bizkaia</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro España, MD</last_name>
      <phone>+34.944.00.70.00</phone>
    </contact>
    <investigator>
      <last_name>Pedro España, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>València</city>
        <state>Valencia</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario Menéndez, MD</last_name>
      <phone>+34.961.24.40.00</phone>
    </contact>
    <investigator>
      <last_name>Rosario Menéndez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miquel Ferrer, MD</last_name>
      <phone>+34.227.54.00</phone>
    </contact>
    <investigator>
      <last_name>Miquel Ferrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrian Ceccato, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Alfageme, MD</last_name>
      <phone>+34.902.50.50.61</phone>
    </contact>
    <investigator>
      <last_name>Inmaculada Alfageme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>David Garcia Cinca</investigator_full_name>
    <investigator_title>Study Applicant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

